Does IBRITUMOMAB TIUXETAN Cause Off label use? 83 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 83 reports of Off label use have been filed in association with IBRITUMOMAB TIUXETAN (Zevalin). This represents 13.7% of all adverse event reports for IBRITUMOMAB TIUXETAN.
83
Reports of Off label use with IBRITUMOMAB TIUXETAN
13.7%
of all IBRITUMOMAB TIUXETAN reports
41
Deaths
29
Hospitalizations
How Dangerous Is Off label use From IBRITUMOMAB TIUXETAN?
Of the 83 reports, 41 (49.4%) resulted in death, 29 (34.9%) required hospitalization, and 4 (4.8%) were considered life-threatening.
Is Off label use Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IBRITUMOMAB TIUXETAN. However, 83 reports have been filed with the FAERS database.
What Other Side Effects Does IBRITUMOMAB TIUXETAN Cause?
Sepsis (123)
Meningitis tuberculous (111)
Thrombocytopenia (75)
Myelodysplastic syndrome (72)
Progressive multifocal leukoencephalopathy (62)
Mucosal inflammation (56)
Neutropenia (55)
Anaemia (53)
Febrile neutropenia (49)
Acute myeloid leukaemia (44)
What Other Drugs Cause Off label use?
RITUXIMAB (39,751)
INFLIXIMAB (34,801)
DENOSUMAB (34,612)
METHOTREXATE (24,020)
VEDOLIZUMAB (21,017)
ETANERCEPT (20,178)
TOCILIZUMAB (18,256)
PREDNISONE (17,867)
LENALIDOMIDE (17,017)
ADALIMUMAB (16,417)
Which IBRITUMOMAB TIUXETAN Alternatives Have Lower Off label use Risk?
IBRITUMOMAB TIUXETAN vs IBRUTINIB
IBRITUMOMAB TIUXETAN vs IBUPROFEN
IBRITUMOMAB TIUXETAN vs IBUPROFEN LYSINE
IBRITUMOMAB TIUXETAN vs IBUPROFEN UNKNOWN PRODUCT
IBRITUMOMAB TIUXETAN vs IBUPROFEN\IBUPROFEN